plus sign (+) inside this box + PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/P	то			Complete if F	Known	1
INITO	DAGATIO	N DICA	LOCUEE	Application Number	10/516,745		
_			LOSURE	Filing Date	December 4	4, 2004	
STAT	TEMENT	BY AP	PLICANT	First Named Inventor	Florian LAN	IG et al.	
				Group Art Unit	-Unknown	1647	
	(use as many sheets as necessary)			Examiner Name	Unknown	Ian Dang	
Sheet	1	of	2	Attorney Docket Number	RUFF-3	<u> </u>	

	NON PATENT LITERATURE DOCUMENTS							
Examiner initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(a), volume-issue number(s), publisher, city and/or country where published.	T?					
/I.D./	1	"The Merck Index, 13 th Edition" 2001, Merck & Co., INC., WHITEHOUSE STATION, NJ XP002267642.						
	2	"Phosphorylation of Nedd4-2 by Sgk1 regulates epithelial Na+ channel cell surface expression" Christophe Debonneville et al.; The EMBO Journal Vol. 20 No. 24 pp. 7052-7059, 2001.						
	3	"Evidence for an electrogenic, negatively protein-kinase-A-modulated, Na+-dependent HC0-3 transporter in human lymphocytes" L.A. de la Rose et al.; Pfluegers Arch –Eur J. Physiol (1999) 437:935-943.						
	4	Cellular Physiology and Biochemistry; Cell Physiol Biochem 2000; 10: 187-194 "The Shrinkage-activated Na+ Conductance of Rat Hepatocytes and its Possible Correlation to rENaC" Christoph Boehmer et al.						
	5	"Epithelial sodium channel regulated by aldosterone-induced protein sgk" Sei-Yu CHEN et al.; Proc. Natl. Acad Sci, USA vol. 96, pp. 2514-2519, March 1999.						
	6	"Sgk Is an Aldosterone-induced Kianse in the Renal Collecting Duct" Aniko Naray-Fejes-Toth et al.; The Journal of Biological Chemistry 1999 vol. 274, No. 24, Issue of June 11 pp. 16973-16978, 1999.						
	7	"Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy" F. Lang et al.: July 5, 2000 vol. 97 no. 14 8157-8162						
	8	"Regulation of sgk by aldosterone and its effects on the epithelial Na+ channel" Alexander Shigaev et al. Am J Physiol Renal Physiol 278: F613-F619, 2000. Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot 76100, Israel						
	9	Cellular Physiology and Biochemistry "Effects of the Senne/Threonine Kinase SGK1 on the Epithelial Na-+Channel (EnaC) and CFTR: Implications for Cystic Fibrosis" Carsten A. WAGNER et al.; Cell Physiol Biochem 2001;11-209-218.						
	10	"Serum-and Glucocorticoid-Regulated Kinase (SGK1) Gene and Blood Pressure" Andreas Busjahn, et al.; 2002 American Heart Association, Inc. pp. 256-260.						
	11	"Immediate-early Transcriptional Regulation and Rapid mRNA Turnover of a Putative Serine/Threonine Protein Kinase" Melanie K. Webster et al; The Journal of Biological Chemistry vol. 268, No. 16. Issue of June 5 pp. 11482-11485, 1993.						
	12	"Characterization of sgk, a Novel Member of the Serine/Threonine Protein Kinase Gene Family Which is Transcriptionally Induced by Glucocorticoids and Serum" Melanie K. Webster et al.; Molecular and Cellular Biology, Apr. 1993, pp. 2031-2040.						
	13	"The Regulation and Physiological Roles of Serum and Glucocorticoid-Induced Protein Kinase" Florian Lang et al.; Published 13 November 2001 pp.1-11.						
	14	"Serum and Glucocorticoid-Inducible Kinase (SGK) is a Target of the P1 3-Kinase-Stimulated signaling Pathway" Jongsun Park et al; The EMBO Journal vol. 18 no. 11 pp. 3024-3033, 1999.						
$\sqrt{}$	15	"Rapid Upregulation of Serum and Glucocorticoid-Regulated Kinase (SGK) Gene Expression by Corticosteroids in Vivo" Francine E. Brennan et al.; Molecular and Cellular Endocrinology 166 (2000) 129-136.						

Please type a plus sign (+) inside this box	+
---	---

of

Sheet

PTO/SB/08A (08-00)

RUFF-3

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Attorney Docket Number

Substitute for form 1449A/PTO Complete if Known Application Number 10/516,745 **INFORMATION DISCLOSURE** Filing Date December 4, 2004 STATEMENT BY APPLICANT First Named Inventor Florian LANG et al. 1647 **Group Art Unit** Unknown (use as many sheets as necessary) Ian Dang **Examiner Name** Unknown-

· · · · · · · · · · · · · · · · · · ·		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
/I.D./	16	"Expression of serum-and glucocorticoid-regulated kinase (sgk) mRNA is up-regulated by GM-CSF and other proinflammatory mediators in human granuclocytes"; R.T. Cowling et al.	
		Journal of Leukocyte Biology Vol. 67, February 2000.	
	17	"Activation of serum-and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2." Takayasu KOBAYASHI et al. Biochem J. (1999) 339-, 319-326	
	18	"Characterization of the structure and regulation of two novel isoforms of serum-and glucocorticoid-induced protein kinase" Takayasu KOBAYASHI et al. Biochem J. (1999) 344,, 189-197.	
	19	"Expression cloning and cDNA sequencing of the Na+/glucose co-transporter" Matthias A. Hediger et al.; Nature vol. 330 26 November 1987.	
\bigvee	20	Cellular Physiology and Biochemistry 'The use of Xenopus laevis Oocytes for the Functional Characteriaztion of Heterologously Expressed Membrane Proteins" Carsten A. Wagner et al. Cellular Physiol Biochem 2000; 10:1-12.	- · · -
			
_			

Examiner	/lan Dang/	Date	07/04/0007	$\overline{}$
Signature	/lan Dany/	Considered	07/24/2007	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box +

Substitute for form 1449A/PTO

Sheet

PTO/SB/08A (08-00)

Under the Paperwork Reduction Act of 1995, no persons an	Approved for through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Otto S. DEPARTMENT OF COMMERCE se required to respond to a collection of information acress it contains a valid OMB control number.
or form 1449A/PTO	Complete If Known U/516745

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

10/516,745 -Unaccigned Application Number December 6, 2004 Filing Date First Named Inventor Florian LANG et al. **Unassigned** 1647 **Group Art Unit**

(use as many sheets as necessary) of

Unaccigned Examiner Name RUFF-3 Attorney Docket Number

Ian Dang

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication of Cited Document Kind Code² Examiner Name of Patentee or Applicant of Cited Document MM-DD-YYYY Number (if known) /I.D./ 4952567 August 28, 1990 /I.D./ 2 2003055019 March 20, 2003


		F	oreign Patent Docu	ment			Pages, Columns, Lines, Where	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	
/I.D./	3	wo	0062781	1 .	Waldegger Siegfried	October 26, 2000		
	4	wo	9964062		Pharmacia & Up John AB	December 16, 1999		
	5	wo	8911295		Demeyts Pierre	November 30, 1989		Equv to cite
	6	DE	4218669		Max-Planck- Gesellschaft	September 2, 1993		
V	7	wo	0018918		Curagen Corp.	April 6, 2000		Equv to cite

Examiner Signature	/lan Dang/	Date Considered	07/24/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for	r form 1449A/PT	· ·		Complete if Known			
INICOD	B4 A TION	I DISCL	OCUPE:	Application Number	Unassigned	10/516,745	
			OSURE	Filing Date	December 6, 2	004	
STATEMENT BY APPLICANT				First Named Inventor	Florian LANG	et al.	
				Group Art Unit	-Unassigned-	1647	
(use as many sheets as necessary)				Examiner Name	-Unassigned	Ian Dang	
Sheet	2	of	2	Attorney Docket Number	RUFF-3		

***		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, sympostum, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/I.D./		BUSJAHN A ET AL: "SERUM-AND GLUCOCORTICOID-REGULATED KINASE (SGK1) GENE AND BLOOD PRESSURE" HYPERTENSION , XX, XX, Bd. 40, Nr. 3, September 2002 XP008016812	
· /I.D./	9	OKU A ET AL: "T-1095, AN INHIBITOR OF RENAL NA+-GLUCOSE COTRANSPORTERS, MAY PROVIDE A NOVEL APPROACH TO TREATING DIABETES; DIABETES, NEW YORK, NY, US. Bd. 48, September 1999 XP002950525	
/I.D./		BARFULL ANNA ET AL: "REGULATION OF SGLT1 EXPRESSION IN RESPONSE TO Na(+) INTAKE." AMERICAN JOURNAL OF PHYSIOLOGY. REGULATORY, INTEGRATIVE AND COMPARATIVE PHYSIOLOGY. UNITED STATES MAR 2002, Bd. 282, Nr. 3, March 2002 XP002267641.	

<u></u>		T 2	
Examiner	/lon Dona/	Date	07/04/0007
Signature	/lan Dang/	` Considered	07/24/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.